YGYangfan Guo

Yangfan Guo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yangfan Guo has a total of 76 co-authors. Here are the top co-authors by number of shared publications:

  • Wei Luo

    Yan'an Hospital Affiliated To Kunming Medical University, Central Laboratory, Kunming, China; Yan'an Hospital Affiliated To Kunming Medical University, Precision Medicine Center, Kunming, China

    5 shared publications
  • Qi Wang

    Yan'an Hospital Affiliated To Kunming Medical University, Central Laboratory, Kunming, China; Yan'an Hospital Affiliated To Kunming Medical University, Precision Medicine Center, Kunming, China

    4 shared publications
  • Xiaoqing Li

    Yan'an Hospital Affiliated To Kunming Medical University, Central Laboratory, Kunming, China; Yan'an Hospital Affiliated To Kunming Medical University, Precision Medicine Center, Kunming, China

    4 shared publications
  • Fang Yang

    Yunnan Key Laboratory of Tumor Immunological Prevention and Control, Kunming, China; Yan'an Hospital Affiliated To Kunming Medical University, Department of Pathology, Kunming, China

    3 shared publications
  • Haiyan Guo

    Yan'an Hospital Affiliated To Kunming Medical University, Central Laboratory, Kunming, China; Yunnan Key Laboratory of Tumor Immunological Prevention and Control, Kunming, China

    3 shared publications
  • Jia Jia

    Fujungenetics Biotechnology Co., Ltd, Shanghai, China

    3 shared publications

Latest Publications

  • Open Access

    Human Umbilical Cord Mesenchymal Stem Cells in Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) Therapy: Mechanisms, Clinical Efficacy, and Future Perspectives

    by Hua Jiang, Hui Wang, Yankun Zhu, Chunyan Yi, Jinli Liu, Ruisi Zhao, Jianpeng Gao, Anmin Cao, Yangfan Guo

    There is currently no approved drug treatment for metabolic dysfunction-related fatty liver disease (MAFLD). Umbilical cord-derived mesenchymal stem cells (UC-MSCs) show therapeutic potential, but their mechanism of action is remains incompletely understood. Different from previous reviews that focused on a single pathway, this article presents three important contributions: First, it constructs an integrated “multi-target synergy network” model, clarifying how UC-MSCs coordinate and regulate the inflammatory, metabolic and fibrotic processes through the interactions between the AMPK/mTOR, Nrf2/HO-1 and TGF-β/Smad pathways; Second, it systematically assesses recent clinical trials (2022–2025), identifying several unaddressed barriers to transformation, including the lack of histological endpoint indicators, batch-to-batch differences, and the absence of dose exploration studies; Third, we integrate the latest developments from 2024 to 2025, particularly mitochondrial transfer (mediated by tunnel nanotubes and accompanied by quantitative efficacy data) and exosome circular RNA networks \(\:\text{circ}\text{−}\text{Tulp}\text{4/}\text{miR}\text{−34}\text{a}\text{/}\text{NF}\text{−}\text{κBaxis}\), which have not been covered in previous reviews. Based on the above analysis, we also propose specific suggestions for standardized GMP production, mandatory genomic stability testing, and long-term safety registration. This review provides a comprehensive analysis of elaborates on the treatment of MAFLD with UC-MSCs from a mechanistic and translational perspective, based on the extensive updates of relevant literature.

  • Open Access

    A spatial immune scoring system based on the tumor microenvironment features improves prognostic stratification in lung adenocarcinoma

    by Wei Luo, Jia Jia, Qi Wang, Xiaoqing Li, Fang Yang, Yongtian Zhao, Zilu Li, Lin Li, Xiaodan Wang, Mingyao Meng, et al.

  • Open Access

    Case Report: A typical triad of Danon disease caused by a LAMP2 splice-donor variant with multilevel functional validation

    by Yang Hu, Shijie Liu, Qian Liu, Bosu Liu, Jinting Zhang, Huipeng Su, Li Yang, Lulu Gan, Yangfan Guo, Yan He

    Danon disease is a rare X-linked dominant disorder caused by pathogenic variants in LAMP2 , typically presenting with cardiomyopathy, skeletal myopathy, and intellectual disability, and showing a severe course in males. In this study, we report the case of a 29-year-old Han Chinese male with the classic triad, plus macular degeneration and a complex neuromuscular phenotype including axonal–demyelinating sensorimotor polyneuropathy. Whole-exome sequencing identified a hemizygous splice-donor variant in LAMP2 (NM_002294.2:c.928 + 1G > A). A functional analysis in peripheral blood with matched controls experimentally confirmed markedly reduced LAMP2 mRNA levels and decreased LAMP2 protein expression, supporting the variant as a loss-of-function allele. The patient rapidly progressed to end-stage heart failure and died 18 months after diagnosis, highlighting the severe multisystem impact of this variant. This case expands the functional evidence for pathogenic LAMP2 splice-site variants and suggests peripheral nervous system involvement in severe multisystem Danon disease.

  • Open Access

    A spatial immune scoring system based on the tumor microenvironment features improves prognostic stratification in lung adenocarcinoma

    by Wei Luo, Qi Wang, Xiaoqing Li, Fang Yang, Yongtian Zhao, Zilu Li, Jia Jia, Haiyan Guo, Wanli Zheng, Liqiong Wang, et al.

    The spatial heterogeneity of the tumor immune microenvironment (TME) in lung adenocarcinoma (LUAD) limits the prognostic accuracy of traditional TNM staging. Moreover, conventional T cell based immune scores established for other solid tumors fail to effectively stratify patient outcomes in LUAD. To address this, we applied quantitative multiplex immunofluorescence to map the spatial immune contexture of LUAD and developed the Lung Cancer Immune Score (LCIS). This framework integrates four key biomarkers: CD68⁺HLA-DR⁺ macrophages, CD20⁺ B cells, PD-1⁺ cells, and Ki67⁺ proliferating tumor cells, to quantify the balance between tumor proliferation and host anti-tumor immunity across the tumor core and invasive margin. High LCIS scores independently predicted improved overall survival in both the discovery (p=0.02) and independent validation (p = 0.017) cohorts, outperforming conventional clinical parameters and single biomarkers. Specifically, LCIS effectively sub-stratified patients with Stage II and III LUAD into refined prognostic groups, resolving the prognostic ambiguity within the same TNM stage. Overall, by quantifying the interaction between tumor proliferation and antigen-directed immune activation, the LCIS serves as a spatial biomarker to refine prognosis and inform personalized therapy in LUAD.

  • Integrative Analysis of Targeted Genomic Profiling and Immune Cell Infiltration in the Prognosis of Lung Adenocarcinoma

    by Xuechun Wang, Wei Luo, Xuehong Gu, Teng Hu, Guping Shi, Jia Jia, Hongmei Qiu, Yangfan Guo

    The prognosis of lung adenocarcinoma (LUAD) is traditionally evaluated via tumor-node-metastasis (TNM) staging, which does not account for the patient's immune status. This protocol integrates genomic profiling and immune microenvironment analysis to facilitate a more comprehensive postoperative prognostic evaluation. The method involves a retrospective analysis of paraffin-embedded tumor tissues using two primary techniques. First, next-generation sequencing (NGS) is performed with a customized 37-gene panel to identify mutations in driver genes and variants of uncertain significance. Second, multiplex immunofluorescence (mIF) is utilized to target markers including HLA-DR, CD68, CD163, CD206, PD-L1, and PanCK. This enables the quantification of spatial distribution and density for specific immune cell subpopulations across various tumor regions. This integrated approach enables the simultaneous assessment of genomic heterogeneity and tumor-infiltrating immune cell characteristics. The resulting data identifies specific combinations of mutational profiles-such as EGFR status-and immune cell densities. These integrated combinations enable the study of their collective impact on patient survival, offering a promising approach for the development of future lung cancer prognostic models. This protocol demonstrates a robust method for characterizing the complex biological features of the LUAD tumor microenvironment.

  • Open Access

    A retrospective cohort study identifies differential diabetes progression among Han, Dai, and Yi groups in Yunnan

    by Yanmei Liu, Zilu Li, Jian Zhang, Shuangyue Li, Xiaoqing Li, Mingyao Meng, Shaowen Liu, Wei Luo, Xilin Kang, Yan Yu, et al.

  • Open Access

    Integrative Multi-omics Deciphers the Assembly Rules of the Human Skin Microbiome and Highlights Lipid-Mediated Niche Partitioning

    by Huizhen Chen, Wei Luo, Zhiming Guo, Zhiming Li, Jianju Feng, Shensong Cao, Qi Wang, Zhenglong Gu, Jean Krutmann, Jiucun Wang, et al.

    Understanding the ecological assembly mechanisms of microbial communities is critical for deciphering host-microbiota interactions, however, such processes remain poorly characterized in cutaneous ecosystems. By profiling a non-industrialized rural cohort, this study deciphers the assembly rules governing the human skin microbiome and reveals an evolutionarily conserved core microbiota structured by niche selection. Microbial α-diversity peaks when C. acnes and M. osloensis reach equilibrium, supporting the Intermediate Disturbance Hypothesis. Host lipids, rather than aqueous compounds, emerged as the primary drivers of microbial niche partitioning. We further demonstrate that C. acnes and Malassezia restricta function as core metabolic engineers, expressing diverse lipases that hydrolyze triglycerides (TGs) into free fatty acids (FFAs), thereby maintaining skin surface lipid homeostasis (∼85% TG + FFA). Notably, virtually all skin surface FFAs are microbially derived and function as “public goods”, enabling cross-feeding that supports auxotrophic members and fosters mutualistic interactions. Importantly, in vitro coculture experiments confirm that C. acnes establish a survival niche for M. restricta . Our findings support a paradigm shift from a taxonomic to a functional understanding of the skin ecosystem, underscoring microbial lipid metabolism as a central orchestrator of ecological stability and a promising target for therapeutic intervention. Abstract Figure: GRAPHIC ABSTRACT


  • Open Access

    Recent advances in machine learning for precision diagnosis and treatment of esophageal disorders

    by Shao-Wen Liu, Peng Li, Xiao-Qing Li, Qi Wang, Jin-Yu Duan, Jin Chen, Ru-Hong Li, Yang-Fan Guo

    The complex pathophysiology and diverse manifestations of esophageal disorders pose challenges in clinical practice, particularly in achieving accurate early diagnosis and risk stratification. While traditional approaches rely heavily on subjective interpretations and variable expertise, machine learning (ML) has emerged as a transformative tool in healthcare. We conducted a comprehensive review of published literature on ML applications in esophageal diseases, analyzing technical approaches, validation methods, and clinical outcomes. ML demonstrates superior performance: In gastroesophageal reflux disease, ML models achieve 80%-90% accuracy in potential of hydrogen-impedance analysis and endoscopic grading; for Barrett’s esophagus, ML-based approaches show 88%-95% accuracy in invasive diagnostics and 77%-85% accuracy in non-invasive screening. In esophageal cancer, ML improves early detection and survival prediction by 6%-10% compared to traditional methods. Novel applications in achalasia and esophageal varices demonstrate promising results in automated diagnosis and risk stratification, with accuracy rates exceeding 85%. While challenges persist in data standardization, model interpretability, and clinical integration, emerging solutions in federated learning and explainable artificial intelligence offer promising pathways forward. The continued evolution of these technologies, coupled with rigorous validation and thoughtful implementation, may fundamentally transform our approach to esophageal disease management in the era of precision medicine.


  • Open Access

    AD-GCN: A novel graph convolutional network integrating multi-omics data for enhanced Alzheimer’s disease diagnosis

    by Zilu Li, Qingyun Li, Xiaoqing Li, Wei Luo, Haiyan Guo, Chunyan Zhao, Canzhen Yang, Anke Xie, Kai Hu, Yangfan Guo

    Alzheimer’s disease (AD) etiology is complex, influenced by demographic risk factors such as age, sex, and educational level, alongside multi-omics factors derived from genomics, transcriptomics, and epigenomics. Advancements in multi-omics technology present both challenges and opportunities for AD diagnosis, enabling a more comprehensive understanding of the complex interactions among contributing factors, with the goal of improving diagnostic accuracy. To address this challenge, we propose a novel feature fusion approach in this study, AD-GCN, which integrates multi-omics data and their interaction networks to achieve more precise diagnosis and analysis of AD. In this study, we applied polygenic risk score and random forest algorithms for feature selection on genetic variation and methylation data. We then developed an AD-GCN for both multi-omics and single-omics classification tasks and compared its performance with that of machine learning ensemble methods. The experimental results demonstrated that multi-omics classification significantly outperformed single-omics classification, with AD-GCN surpassing the machine-learning ensembles. These findings highlight AD-GCN’s strong potential to enhance AD diagnosis and improve accuracy in differentiating disease stages by integrating interactions across omics data, laying a solid foundation for the development of more precise and personalized AD diagnostic models.


  • Open Access

    AIP, fatty liver, and HbA1c as modifiers of the C-index and diabetes risk relationship

    by Yanmei Liu, Rui Shi, Huiying Cao, Jian Zhang, Shuangyue Li, Xilin Kang, Yongjuan Ma, Yudian Wu, Yangfan Guo, Lei Feng

    Background and aims: Recent studies have suggested an interplay between conicity index (C-index)-related diabetes risk and lipid burden. It is plausible that the atherogenic index of plasma (AIP), fatty liver, and HbA1c mediate the association between C-index and diabetes risk, though this has not been fully explored. This study explored whether AIP, fatty liver, and HbA1c mediate the relationship between C-index and diabetes risk, as well as their combined effect. Methods: Data from 15,453 participants in the NAGALA Cohort were analyzed (median follow-up 5.39 years). Restricted Cubic Spline (RCS) and univariate Cox regression models adjusted for risk factors were used to assess the role of AIP in modifying the C-index-diabetes relationship. Mediation analysis assessed the contributing factors, and predictive models for diabetes were established. Results: Among normoglycemic individuals, the AIP and C-index remained significantly and positively associated with diabetes risk. Higher AIP levels strengthened the C-index-diabetes association, particularly in the AIP range of 0.11-≤1.21. In the initial model, hazard ratios (HRs) for those in the fourth quartile of the C-index distribution in this group showed a significant HR of 2.22 (1.37–3.59). As fatty liver and HbA1c levels were progressively adjusted, the HRs gradually decreased, but a significant HR of 1.70 (1.05–2.76) was retained in the fully adjusted model. No significant association was observed in the other AIP strata. Furthermore, AIP, fatty liver, and HbA1c mediated the relationship between C-index and diabetes risk, with mediation effects of 9.8%, 25.0%, and 13.4%, respectively. Notably, the combined model incorporating AIP, fatty liver, HbA1c, and the C-index achieved the highest predictive performance (AUC = 0.86), outperforming the C-index alone (AUC = 0.68). Conclusions: C-index was significantly associated with diabetes risk, modified by AIP, fatty liver, and HbA1c. These findings emphas ize the importance of AIP along with the C-index, particularly in the context of fatty liver and HbA1c, for diabetes risk screening and management.